雾化吸入支气管扩张剂对不同肺部疾病肺功能检查结果的影响研究

发布时间：2019-01-08 15:51

【摘要】：目的评价雾化吸入支气管扩张剂硫酸沙丁胺醇溶液对不同肺部疾病肺功能检查结果的影响。方法本文采用随机对照试验设计方法,选择符合纳入排除标准的门诊和住院的肺部疾病患者200例,随机分为试验组和对照组;所有纳入研究对象常规肺功能检测后,试验组受试者采用压缩空气式雾化器雾化吸入硫酸沙丁胺醇溶液2.5mL/5mg,对照组采用定量吸入装置喷雾吸入硫酸沙丁胺醇气雾剂400μg。休息20 min后,重复检测肺功能。检测用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、1秒率(FEV1%)、最大呼气中期流量(FEF25%~75%)、最大呼气末期流量(FEF75%~85%)、最大呼吸流量(PEF),计算用药后各指标的改善量和改善率。根据患者最终临床诊断分为四类(哮喘患者67例,COPD患者74例,哮喘合并COPD患者31例,其他肺部疾病患者28例)进行亚组分析。结果两种用药方式之间比较,哮喘患者试验组FEV1%的改善量和改善率略高于对照组,其他指标的改善量和改善率略低于对照组,但均无显著差异(P0.05);COPD患者试验组FVC的改善量和改善率略低于对照组,其他指标的改善量和改善率略高于对照组,但仅FEF25%~75%的改善率有显著差异(P0.05),FEF25%~75%的改善量及其余指标的改善量和改善率均无显著差异(P0.05);哮喘合并COPD患者试验组用药后FEV1%、FEF25%~75%、FEF75%~85%的改善量和改善率均低于对照组(P0.05或P0.01),试验组FVC、PEF的改善量和改善率高于对照组,FEV1的改善量和改善率低于对照组,但无显著差异(P0.05);其他肺部疾病患者试验组FVC、FEF75%~85%、PEF的改善量和改善率高于对照组,FEV1、FEV1%、FEF25%~75%的改善量和改善率低于对照组,但均无显著差异(P0.05)。结论与定量吸入装置喷雾吸入硫酸沙丁胺醇气雾剂比较,雾化吸入硫酸沙丁胺醇溶液COPD患者和哮喘合并COPD患者FEV1%、FEF25%~75%、FEF75%~85%有影响,而对FVC、FEV1、PEF影响不大。
[Abstract]:Objective to evaluate the effect of aerosol inhalation of salbutamol sulfate on pulmonary function in different lung diseases. Methods A randomized controlled trial design was used to select 200 patients with pulmonary diseases who met the exclusion criteria and were randomly divided into two groups: the experimental group and the control group. After routine pulmonary function test, the subjects in the test group were inhaled with compressed air nebulizer for 2.5 mL / 5 mg of salbutamol sulfate solution, while the control group was sprayed with a quantitative inhaler to inhale 400 渭 g of salbutamol sulfate aerosol. After 20 min rest, pulmonary function was repeatedly measured. Forced expiratory volume (FEV1), 1 second rate (FEV1%), maximum mid-expiratory flow (FEF25%~75%), maximum end-expiratory flow (FEF75%~85%), maximum respiratory flow (PEF),) in forced vital capacity (FVC),) were measured. The improvement quantity and improvement rate of each index after medication were calculated. According to the final clinical diagnosis, the patients were divided into four subgroups: 67 asthmatic patients, 74 COPD patients, 31 asthmatic patients with COPD, and 28 patients with other pulmonary diseases. Results the improvement amount and improvement rate of FEV1% in asthmatic patients group were slightly higher than those in control group, but the improvement rate of other indexes was slightly lower than that of control group, but there was no significant difference (P0.05). The improvement amount and improvement rate of FVC in COPD group was slightly lower than that in control group, and the improvement rate of other indexes was slightly higher than that of control group, but only the improvement rate of FEF25%~75% had significant difference (P0.05). There was no significant difference in the improvement of FEF25%~75%, the improvement of other indexes and the improvement rate (P0.05). The improvement amount and improvement rate of FEV1%,FEF25%~75%,FEF75%~85% in the experimental group with asthma combined with COPD were lower than those in the control group (P0.05 or P0.01), and the improvement amount and the improvement rate of FVC,PEF in the experimental group were higher than those in the control group. The improvement amount and improvement rate of FEV1 were lower than that of control group, but there was no significant difference (P0.05). The improvement of FVC,FEF75%~85%,PEF and the improvement rate of FEV1,FEV1%,FEF25%~75% in other pulmonary diseases group were higher than those in the control group, but there was no significant difference (P0.05). Conclusion compared with the spray inhalation of salbutamol sulfate aerosol in quantitative inhaler, the effect of aerosol inhalation on FEV1%,FEF25%~75%,FEF75%~85% in salbutamol sulfate solution COPD patients and asthmatic patients with COPD is significant, but the effect on FVC,FEV1,PEF is not significant.
【作者单位】：第三军医大学西南医院呼吸科肺功能室;
【分类号】：R563

【相似文献】